Dr. Roxanne Judith Abitbol, MD

Dr. Abitbol practices at South Nassau Dermatology in Levittown, New York.

Dr. Abitbol's NPI, 1841415197, was assigned on April 13, 2007. Dr. Abitbol graduated from New York University School of Medicine in 2003. Dr. Abitbol holds New York license 242570-1.

Dr. Abitbol's primary practice is South Nassau Dermatology, at 2900 Hempstead Turnpike, Levittown, NY 11756 in Nassau County. The practice phone is (516) 766-0345.

Dr. Abitbol's primary practice is South Nassau Dermatology in Levittown, New York. The medical group on file is South Nassau Dermatology. Dmand AI also links Dr. Abitbol to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abitbol practices. Vendor and product names are available with a free account.

Dermatology is Dr. Abitbol's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Abitbol is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Abitbol's licenses on file in 2 states: New York and Rhode Island.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, hives and itchy rashes among the conditions Dr. Abitbol treats.

CMS data shows 6,073 Medicare services from Dr. Abitbol across 34 procedure codes in 2024, for 956 Medicare patients. Medicare paid $349,636 for them. Every service was in an office.

CMS counts 956 Medicare patients who saw Dr. Abitbol in 2024. The largest group is 65 to 74, with 479 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 4% are also on Medicaid. Their average risk score is 0.89, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Abitbol's median patient age at 60, with 69% women.

In 2024, Dr. Abitbol wrote 1,436 Medicare Part D claims for 575 patients. 91% of them were for generic drugs. CMS names the drug for 1,274 of them, across 22 drugs with 11 or more claims each, at $379,392 in total drug cost. In 2023, CMS named 978 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Abitbol for performance year 2024, reported as part of a group. Dr. Abitbol accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 1,540 procedures of skin biopsy by Dr. Abitbol, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 2 papers to Dr. Abitbol. Dr. Abitbol's most frequent co-author is Jodie S. Raffi.

CMS Open Payments shows 730 general payments to Dr. Abitbol from 38 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. Galderma Laboratories, L.P. paid the most, $22,095.

Dmand AI lists 1 award for Dr. Abitbol.

Dr. Abitbol graduated from New York University School of Medicine in 2003. Dr. Abitbol is a member of AAD.

Dr. Abitbol is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.